Quick answer
Krystal Biotech, Inc. (KRYS) reported revenue of $389.1M and net income of $204.8M for the fiscal year ended 2025-12-31, up 33.9% from $290.5M the year before, per its 10-K filed with the SEC on 2026-02-17.
Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2025 (FY ending 2025-12-31) | $389.1M | $204.8M | — |
| 2024 (FY ending 2024-12-31) | $290.5M | $89.2M | — |
| 2023 (FY ending 2023-12-31) | $50.7M | $10.9M | — |
| 2022 (FY ending 2022-12-31) | $0.0M | -$140.0M | — |
| 2021 (FY ending 2021-12-31) | $0.0M | -$69.6M | — |
| 2020 (FY ending 2020-12-31) | — | -$32.2M | — |
| 2019 (FY ending 2019-12-31) | — | -$19.1M | — |
| 2018 (FY ending 2018-12-31) | — | -$10.9M | — |
| 2017 (FY ending 2017-12-31) | — | -$7.9M | — |
| 2016 (FY ending 2016-12-31) | — | -$1.1M | — |
Frequently asked questions
What is Krystal Biotech, Inc.'s annual revenue?
Krystal Biotech, Inc. (KRYS) reported revenue of $389.1M and net income of $204.8M for the fiscal year ended 2025-12-31, up 33.9% from $290.5M the year before, per its 10-K filed with the SEC on 2026-02-17.
What is KRYS's profit margin?
Krystal Biotech, Inc.'s net margin was 52.6% in the fiscal year ended 2025-12-31.
Related
- KNX revenue, net income and debt history (Knight-Swift Transportation Holdings Inc.)
- KO revenue, net income and debt history (Coca Cola Co)
- KR revenue, net income and debt history (Kroger Co)
- KVUE revenue, net income and debt history (Kenvue Inc.)
- KYMR revenue, net income and debt history (Kymera Therapeutics, Inc.)
- L revenue, net income and debt history (Loews Corp)
- LAMR revenue, net income and debt history (Lamar Advertising Co/New)
- LDOS revenue, net income and debt history (Leidos Holdings, Inc.)
Last updated Oct 16, 2026, 10:42 PM ET. Data only, not financial or tax advice.